NASDAQ:AVXL
Anavex Life Sciences Corp.
Anavex Life Sciences Corp. reported net income of −$46.4M in fiscal 2025. The diluted share count rose 2.2%.Summary generated from Anavex Life Sciences Corp.'s SEC filings. Latest annual report filed Aug 28, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−43.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −42 | −51 | −56 | −53 | −51 |
| Net income | −38 | −48 | −48 | −43 | −46 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 28, 2026 - 8-KChange in control
Sep 28, 2026 - 8-KOther events
Sep 9, 2026 - 8-KOther events
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Aug 28, 2026 - 10-Q/AAmended quarterly report for the period ended Dec 31, 2025
Aug 28, 2026 - 10-K/AAmended annual report for the fiscal year ended Sep 30, 2025
Aug 28, 2026